Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML

SIMPLE SUMMARY: About 50% of adults with chronic myeloid leukemia (CML) in sustained deep molecular response (DMR) to tyrosine kinase inhibitors (TKI) could discontinue the treatment permanently without molecular relapse. Recommendations regarding discontinuation apply only for adults because childh...

Descripción completa

Detalles Bibliográficos
Autores principales: Millot, Frédéric, Suttorp, Meinolf, Ragot, Stéphanie, Leverger, Guy, Dalle, Jean-Hugues, Thomas, Caroline, Cheikh, Nathalie, Nelken, Brigitte, Poirée, Marilyne, Plat, Geneviève, Versluys, Birgitta, Lausen, Birgitte, Borisevich, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392145/
https://www.ncbi.nlm.nih.gov/pubmed/34439257
http://dx.doi.org/10.3390/cancers13164102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392145/
https://www.ncbi.nlm.nih.gov/pubmed/34439257
http://dx.doi.org/10.3390/cancers13164102

Ejemplares similares